Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-04958242 In Subjects With Age-Related Sensorineural Hearing Loss
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Sensorineural hearing loss
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Dec 2014 New trial record